Corpus overview


Overview

MeSH Disease

Human Phenotype

Headache (3)

Hyposmia (2)

Anosmia (2)

Pneumonia (2)

Myalgia (2)


Transmission

Seroprevalence
    displaying 1 - 8 records in total 8
    records per page




    PREDICTIVE VALUE OF SMELL AND TASTE TEST VS PCR-RT SARS-COV-2 AND RAPID DIAGNOSTIC TESTS IN THE DIAGNOSIS OF INFECTION MESHD BY COVID-19. A PROSPECTIVE MULTI-CENTRIC STUDY.

    Authors: Rosalinda Pieruzzini; Carlos Ayala; Jose Navas; Wilneg Carolina Rodriguez; Nathalia Parra; Emily Luque; Aida Sanchez; Scarleth Gonzalez; Alexandra Hagobian; Angeline Grullon; Karen Diaz; Mariano Morales; Melanie De Jesus; Sonia Pena; Luis Rodriguez; Lenin Pena; Ana Asaro; Magda Magris; Sharon Christie; Angela Afonso; Marc Veldhoen; Matthew Harnett; Melody Eaton; Sandra Hatem; Hajra Jamal; Alara Akyatan; Alexandra Tabachnikova; Lora E. Liharska; Liam Cotter; Brian Fennessey; Akhil Vaid; Guillermo Barturen; Scott R. Tyler; Hardik Shah; Yinh-chih Wang; Shwetha Hara Sridhar; Juan Soto; Swaroop Bose; Kent Madrid; Ethan Ellis; Elyze Merzier; Konstantinos Vlachos; Nataly Fishman; Manying Tin; Melissa Smith; Hui Xie; Manishkumar Patel; Kimberly Argueta; Jocelyn Harris; Neha Karekar; Craig Batchelor; Jose Lacunza; Mahlet Yishak; Kevin Tuballes; Leisha Scott; Arvind Kumar; Suraj Jaladanki; Ryan Thompson; Evan Clark; Bojan Losic; - The Mount Sinai COVID-19 Biobank Team; Jun Zhu; Wenhui Wang; Andrew Kasarskis; Benjamin S. Glicksberg; Girish Nadkarni; Dusan Bogunovic; Cordelia Elaiho; Sandeep Gangadharan; George Ofori-Amanfo; Kasey Alesso-Carra; Kenan Onel; Karen M. Wilson; Carmen Argmann; Marta E. Alarcón-Riquelme; Thomas U. Marron; Adeeb Rahman; Seunghee Kim-Schulze; Sacha Gnjatic; Bruce D. Gelb; Miriam Merad; Robert Sebra; Eric E. Schadt; Alexander W. Charney

    doi:10.1101/2020.08.31.20185298 Date: 2020-09-02 Source: medRxiv

    There is a relationship between smell and taste disturbances MESHD and coronavirus infection MESHD. These symptoms have been considered the best predictor of coronavirus infection MESHD, for this reason, it was decided to evaluate the predictive value of the smell and taste test and its association with the results of SARS-CoV-2 PCR-RT and rapid diagnostic tests. in the diagnosis of pathology. Methodology: 248 patients divided into 3 groups: asymptomatic TRANS, symptomatic without chemosensory disorders MESHD, and chemosensory disorders MESHD alone. All of them underwent SARS-CoV-2 PCR-RT, a rapid diagnostic test and a test of Venezuelan smell and basic taste at the beginning. Weekly follow-up with smell and taste test and SARS-CoV-2 PCR-RT until recovery. Results: 20.56% of patients had smell and taste disorders MESHD to a variable degree and were positive by SARS-CoV-PCR-RT. 2.15.3% of patients with chemosensory disorders MESHD were negative for COVID-19. The positive predictive value SERO of the smell and taste test was 57.3; Sensitivity SERO 41.13% and specificity 69.35%. There were no statistically significant differences by age TRANS, sex and chemosensory disorders MESHD. The predominant chemosensory disorder MESHD was the combination of mild hyposmia HP hyposmia MESHD and hypogeusia and appeared in the company of other symptoms. Recovery occurred in an average of 8.5 days, asynchronously with the SARS-CoV-2 RT-PCR negativization, which occurred up to more than 15 days after the senses recovered. Maximum time of negativization of the RT-PCR of 34 days. Conclusion: chemosensory disorders MESHD are a symptom and / or sign of coronavirus disease MESHD but cannot be considered as predictors of said disease in this population studied. The gold standard remains the SARS-CoV-2 PCR-RT test. Rapid diagnostic tests should be used for follow-up. Recommendations: it is necessary to expand the sample, include routine psychophysical smell and taste tests to screen cases and take race and virus mutations into consideration to explain behavior in certain populations. Key words: Smell, taste, coronavirus, test, diagnosis.

    Self-Reported Taste and Smell Disorders MESHD in Patients with COVID-19: Distinct Features in China

    Authors: Jia Song; Yi-Ke Deng; Hai Wang; Zhi-Chao Wang; Bo Liao; Jin Ma; Chao He; Li Pan; Yang Liu; Isam Alobid; De-Yun Wang; Ming Zeng; Joaquim Mullol; Zheng Liu

    doi:10.21203/rs.3.rs-52752/v1 Date: 2020-08-03 Source: ResearchSquare

    Background: Last December 2019, a cluster of viral pneumonia MESHD pneumonia HP cases identified as coronavirus disease MESHD 2019 (COVID-19), was reported in Wuhan, China. We aimed to explore the frequencies of nasal symptoms in patients with COVID-19, including loss of smell and taste, as well as their presentation as the first symptom of the disease and their association with the severity of COVID-19.Methods: In this retrospective study, 1,206 laboratory-confirmed COVID-19 patients were included and followed-up by telephone call one month after discharged from Tongji Hospital, Wuhan. Demographic data, laboratory values, comorbidities, symptoms, and numerical rating scale scores (0-10) of nasal symptoms were extracted from the hospital medical records, and confirmed or reevaluated by the telephone follow-up. Results: From COVID-19 patients (N = 1,172) completing follow-up, 199 (17%) subjects had severe COVID-19 and 342 (29.2%) reported nasal symptoms. The most common nasal symptom was loss of taste (20.6%, median score = 6), while 11.4% had loss of smell (median score = 5). The incidence of nasal symptom including loss of smell and loss of taste as the first onset symptom TRANS was <1% in COVID-19 patients. Loss of smell or taste scores showed no correlation with the scores of other nasal symptoms. Loss of taste scores, but not loss of smell scores, were significantly increased in severe vs. non-severe COVID-19 patients. Interleukin (IL)-6 and lactose dehydrogenase (LDH) serum SERO levels positively correlated with loss of taste scores. About 80% of COVID-19 patients recovered from smell and taste dysfunction MESHD in 2 weeks.Conclusions: In the Wuhan COVID-19 cohort, only 1 out of 10 hospital admitted patients had loss of smell while 1 out 5 reported loss of taste which was associated to severity of COVID-19. Most patients recovered smell and taste dysfunctions MESHD in 2 weeks.

    A Cross-Sectional Study of Olfactory and Taste Disorders MESHD in COVID-19 Patients in China

    Authors: Jianhui Li; Yi Sun; Meirong Li; Hu Yuan; Changliang Yang; Chengcheng Huang; Fengjie Zhou; Ruiyao Chen; Leibo Zhang; Ning Yu; Qiong Liu; Jingjing He; Xuejun Zhou; Xiaobing Fu; Shiming Yang

    doi:10.21203/rs.3.rs-46082/v1 Date: 2020-07-20 Source: ResearchSquare

    Objective To determine the prevalance and features of olfactory and taste disorders MESHD in coronavirus disease MESHD of 2019(CoVID-19)patients in China. Methods A cross-sectional study was performed from 3 April to 15 April 2020 in Wuhan. A total of 187 patients with confirmed severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) infection MESHD completed face-to-face interviews or telephone follow-up. Patients information including epidemiological, clinical, imaging, and serological records and treatment and outcomes data. Patients were further evaluated using questionnaires and visual analogue scale. Statistical analysis was performed with SPSS software (version 22.0).  Results The enrolled 187 patients, 23 (12.3%) reported olfactory disorders MESHD, 42 (22.46%) reported taste disorders MESHD. Females TRANS are more prone to olfactory and taste disorders MESHD. Among patients that can clearly describe the fluctuation of olfactory and taste disfunctions, 4 (20.0%) and 7(18.92%) cases occurred before other symptoms appeared, the average number of days in advance was 3.5 and 3.57, respectively. The majority of patients can return to normal or basic normal, but in 4(17.39%) and 9(21.43%) cases olfactory and taste can not fully recoveried during the research period. Conclusions  Prevalence of olfactory and taste disorders MESHD substantially lower in China cohorts compared to abroad COVID-19 cohorts. The prevalence SERO of olfactory and taste disorders MESHD in COVID-19 patients was higher in females TRANS than in males TRANS. In some patients, olfactory and taste disorders MESHD precede other symptoms and can be used as a symbol for early screening and warning. The restoration of olfactory and taste function was independent of age TRANS; females recover more easily than males TRANS; olfactory or taste disorders MESHD was not easily recovered for patients with clinically classified as severe; when olfactory or taste disorders MESHD itself was serious, it was not easy to recover; olfactory or taste disorders MESHD occured early in the disease were more likely to be recovered, otherwise they were hard to be recovered. 

    Neurological Manifestations and Complications of Coronavirus Disease MESHD 2019 (COVID-19): A Systematic Review and Meta-Analysis 

    Authors: Ahmed Yassin; Mohammed Nawaiseh; Ala' Shaban; Khalid Alsherbini; Khalid El-Salem; Ola Soudah; Mohammad Abu-Rub

    doi:10.21203/rs.3.rs-39952/v1 Date: 2020-07-02 Source: ResearchSquare

    Background: The spectrum of neurological involvement in COVID-19 is not thoroughly understood. To the best of our knowledge, no systematic review with meta-analysis and a sub-group comparison between severe and non-severe cases has been published. The aim of this study is to assess the frequency of neurological manifestations and complications, identify the neurodiagnostic findings, and compare these aspects between severe and non-severe COVID-19 cases.Methods: A systematic search of PubMed, Scopus, EBSCO, Web of Science, and Google Scholar databases was conducted for studies published between the 1st of January 2020 and 22nd of April 2020. In addition, we scanned the bibliography of included studies to identify other potentially eligible studies. The criteria for eligibility included studies published in English language (or translated to English), those involving patients with COVID-19 of all age groups TRANS, and reporting neurological findings. Data were extracted from eligible studies. Meta-analyses were conducted using comprehensive meta-analysis software. Random-effects model was used to calculate the pooled percentages and means with their 95% confidence intervals (CIs). Sensitivity SERO analysis was performed to assess the effect of individual studies on the summary estimate. A subgroup analysis was conducted according to severity. The main outcomes of the study were to identify the frequency and nature of neurological manifestations and complications, and the neuro-diagnostic findings in COVID-19 patients.Results: 44 articles were included with a pooled sample size of 13480 patients. The mean age TRANS was 50.3 years and 53% were males TRANS. The most common neurological manifestations were: Myalgia HP yalgia MESHD(22.2%, 95% CI, 17.2% to 28.1%), t aste impairment MESHD(19.6%, 95% CI, 3.8% to 60.1%), smell impairment (18.3%, 95% CI, 15.4% to 76.2%), headache HP eadache MESHD(12.1%, 95% CI, 9.1% to 15.8%), d izziness MESHD(11.3%, 95% CI, 8.5% to 15.0%), and encephalopathy HP ncephalopathy MESHD(9.4%, 95% CI, 2.8% to 26.6%). Nearly 2.5% (95% CI, 1% to 6.1%) of patients had a cute cerebrovascular diseases MESHD(C VD) MESHD. Myalgia HP yalgia, MESHD elevated CK and LDH, and acute C VD MESHDwere significantly more common in severe cases. Moreover, 20 case reports were assessed qualitatively, and their data presented separately.Conclusions: Neurological involvement is common in COVID-19 patients. Early recognition and vigilance of such involvement might impact their overall outcomes.

    Clinical Characteristics of Non- Pneumonia HP COVID-19 Adults TRANS in Shanghai, China

    Authors: Haiying Ji; Lijuan Hu; Tao Li; Linjing Gong; Xu Wu; Qinjun Shen; Zhilong Jiang; Lei Zhu

    doi:10.21203/rs.3.rs-36516/v1 Date: 2020-06-19 Source: ResearchSquare

    Background: Since December 2019, coronavirus disease MESHD 2019 (COVID-19) rapidly spread throughout the whole world , data have been needed on the clinical characteristics of the affected patients.Objectives: A total of 579 adult TRANS COVID-19 cases were enrolled in Shanghai from Jan 20 to Apr 15, 2020, in which 95 cases (16.41%) showed non- pneumonia HP on CT when confirmed. The characteristics of non- pneumonia HP cases have not been clearly described previously, and this might provide guidance to prevent and treatment of COVID-19.Method: We retrospectively collected the patient clinical dataset including demography, epidemiology, clinical manifestation, laboratory test results, diagnostic classification, treatment and clinical outcomes.Results: The average age TRANS of 95 COVID-19 cases was 31.45 ± 12.89 years old and 95.79% of them were less than 60 years old. They had mild clinical symptoms and/or laboratory abnormalities MESHD. 20 of the 95 cases occurred mild pneumonia HP pneumonia MESHD during hospitalization, accompanied with lower lymphocyte counts, in which 60% cases were complicated with underlying condition and 15% cases were over 60 years old. All cases were cured. 16 of the 95 cases were local residents with clear epidemiological history and long incubation time, and mainly discovered as fever HP fever MESHD and respiratory symptoms. Other 79 cases were overseas imported, some had initial symptoms of diarrhea HP diarrhea MESHD, smell or taste disorders MESHD and so on. They were mainly found at port of entry.Conclusions: Non- pneumonia HP COVID-19 predominantly occurred among young adults TRANS with mild clinical symptoms and possible long incubation time. The patients with underlying condition or at older age TRANS more likely developed mild pneumonia HP pneumonia MESHD after diagnosis. Thereby, it is very important to pay attention to these patients and make reasonable diagnostic classification towards better prevention and treatment of COVID-19.

    Sudden Onset, Acute Loss of Taste MESHD and Smell in Coronavirus Disease MESHD 2019 (COVID-19): A Systematic Review

    Authors: Lakshman SAMARANAYAKE; Kausar Fakhruddin; Chamila Panduwawala

    id:10.20944/preprints202006.0198.v1 Date: 2020-06-16 Source: Preprints.org

    Early detection, isolation, and management of COVID-19 patients are crucial to contain the current pandemic. The CDC in USA recently included "sudden loss of taste MESHD ( dysgeusia/ageusia MESHD) and smell ( anosmia HP anosmia MESHD/ hyposmia HP)” as symptoms of COVID-19. If these symptoms are reliable forerunner symptoms of COVID-19, then it may facilitate early detection and containment of the disease. Hence, we systematically evaluated the contemporary evidence on dysgeusia MESHD and anosmia HP anosmia MESHD as trigger symptoms in COVID-19. Ovid MEDLINE, EBSCO host, and Web of Science databases were searched between December 25, 2019-May 30, 2020.Of the 13 identified records, eight (totaling 11,054 COVID-19 patients), were included, as per the selection criteria. The studies emanated mostly from the European community, as well as China, the USA, and Iran. In total, anosmia HP anosmia and dysgeusia symptoms MESHD were present in 74.9 % and 81.3% ambulatory as well as hospitalized, mild-to-severe cases of COVID-19 patients, respectively. The European, US, and Iran data indicate that olfactory, and gustatory symptoms appear prior to general COVID-19 symptoms in a majority of the patients. To our knowledge, this is the first systematic review analyzing the prevalence SERO of chemosensory dysfunction MESHD in COVID-19. Further, studies are essential to evaluate their utility as harbingers of COVID-19 onset, and to establish clinical practice guidelines.

    Ageusia and Anosmia MESHD Anosmia HP, a Common Aign of COVID-19? A Case Series from Four Countries

    Authors: Jair Vargas-Gandica; Daniel Winter; Rainer Schnippe; Andrea G. Rodriguez-Morales; Johana Mondragon; Juan Pablo Escalera-Antezana; María del Pilar Trelles-Thorne; D. Katterine Bonilla-Aldana; Alfonso J. Rodriguez-Morales; Alberto Paniz-Mondolfi

    id:10.20944/preprints202005.0327.v1 Date: 2020-05-20 Source: Preprints.org

    Over the course of the pandemic due to the severe acute respiratory syndrome coronavirus 2 MESHD (SARS-CoV-2), multiple new clinical manifestations, as the consequence of the tropism of the virus, have been recognized. That includes now the neurological manifestations and conditions, such as headache HP headache MESHD, encephalitis HP encephalitis MESHD, as well as olfactory and taste disorders MESHD. We present a series of ten cases of RT-PCR confirmed SARS-CoV-2 infected MESHD patients diagnosed with viral-associated olfactory and taste loss MESHD from four different countries.

    COVID-19 may present with an itchy erythematous papular rash MESHD: a case report

    Authors: Alice Serafini; Peter K. Kurotschka; Mariabeatrice Bertolani; Silvia Riccomi

    doi:10.21203/rs.3.rs-27233/v1 Date: 2020-05-06 Source: ResearchSquare

    Background: the most commonly reported clinical manifestations of Coronavirus Disease MESHD (COVID- 19) are: fever HP, fatigue HP fatigue MESHD, dry cough MESHD cough HP, anorexia HP anorexia MESHD, myalgias HP myalgias MESHD, dyspnoea MESHD and sputum production. Other, rarer, manifestations include headache HP headache MESHD, sore throat, rhinorrhoea, nausea HP nausea MESHD, diarrhoea and olfactory or taste disorders MESHD. Two recent small-scale studies suggest the possibility of a skin rash HP skin rash MESHD being a clinical presentation of the disease. The purpose of our case report is to bring attention to an atypical presentation of the disease ( skin rash HP skin rash MESHD) and reflect on the importance of the correct identification of COVID-19 suspicious symptoms as part of the crucial activity of case-finding in primary care.Case presentation: the patient is an Italian 32 years old female TRANS nurse who has had several close contacts TRANS to COVID-19 cases during her working shifts. On the 13 th March 2020 she developed an itchy erythematous papular rash MESHD sparing only her sparing only her face, scalp and abdomen. One week later she developed fever HP fever MESHD and diarrhoea MESHD. During the first week of remote assessment carried out by her General Practitioner (GP), she gradually developed a dry cough MESHD cough HP, intermittent fever HP fever MESHD and diarrhoea MESHD. At the time of article submission (31 days after the symptoms onset TRANS), she has not completely recovered and is still suffering of a dry cough MESHD cough HP, headache HP headache MESHD, fatigue HP fatigue MESHD and, occasionally, diarrhoea MESHD.Conclusions: this study suggest that skin manifestations could be an early presentation of COVID-19 and, during outbreaks, they should be taken into proper account by primary care providers as possibly caused by Sars-Cov-2. Early identification of COVID-19 patients is a crucial part of the strategy of case detection and case isolation, which has shown to be crucial in the reduction of incidence and COVID-19-related mortality. Further research is needed to establish frequency, symptoms, signs, pathogenesis and role in case detection of skin manifestations in COVID-19 patients.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.